Page 135 - Informatorium Obat COVID-19 di Indonesia

66. Dong, L., Hu, S., dan Gao, J. 2020. Discovering drugs to
treat coronavirus disease 2019 (COVID-19). Drug Discov
Ther., 14(1):58-60.
67. World Health Organization (WHO). Summaries of evidence
from selected experimental therapeutics, as of October
2018, RnD Blueprint, WHO.
https://www.who.int/ebola/drc-2018/summaries-of-
evidence-experimental-therapeutics.pdf?ua=1. Diakses 27
Maret 2020.
68. Remdesivir for Potential Treatment of COVID-19, Clinical
Trials.https://www.clinicaltrialsarena.
com/projects/remdesivir/. Diakses 27 Maret 2020.
69. World Health Organization (WHO). Summaries of evidence
from selected experimental therapeutics, as of October
2018, RnD Blueprint, WHO.
https://www.who.int/ebola/drc-2018/summaries-of-
evidence-experimental-therapeutics.pdf?ua=1. Diakses 27
Maret 2020.
70. Bergin, C., et al. 2020. Specific Antiviral Therapy in the
Clinical Management of Acute Respiratory Infection with
SARS-CoV-2 (COVID-19), version 1.0. Health Service
Executive.
71. Approved label Tamiflu
®
72. Davis, Brian E. 2010. Pharmacokinetics of oseltamivir: an
oral antiviral for the treatment and prophylaxis of influenza
in diverse populations. J Antimicrob Chemother; 65 Suppl
2: II5 –10
73. AHFS: Assessment of Evidence for COVID-19-Related
Treatments: Updated 3/30/2020.
74. Fehr AR and Perlman S. 2015. Coronaviruses: An Overview
of Their Replication and Pathogenesis. Methods Mol Biol.;
1282:1-23.
75. Dou D, Revol R, Ostbye H, Wang H, Daniels R. 2018.
Influenza A Virus Cell Entry, Replication, Virion Assembly
and Movement. Front. Immunol. 9:1581.
76. Leaflet Cravit® IV. Approved label Badan POM (Dit.
Registrasi Obat).
77. Multicenter collaboration group of Department of Science

126